An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin (Dalteparin Sodium) In Patients Undergoing Major Orthopedic Surgery.
Phase of Trial: Phase IV
Latest Information Update: 10 Feb 2012
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Feb 2012 Actual patient number changed from 494 to 503 as reported by ClinicalTrials.gov.
- 15 Apr 2011 Actual patient numbers reported as 494 by the ClinicalTrials.gov record
- 15 Apr 2011 Status changed from not yet recruiting to completed.